Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | Necitumumab + Pembrolizumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | Necitumumab + Pembrolizumab | Phase II | Actionable | In a Phase II trial, first-line treatment with Keytruda (pembrolizumab) plus Portrazza (necitumumab) resulted in an objective response rate of 76.0%, median progression-free survival of 15.7 months, and median overall survival that was not reached in patients with advanced non-small cell lung cancer with high CD274 (PD-L1) expression (>=50%) (n=50) (Cancer Res (2024) 84 (7_Supplement): CT032). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202) | Full reference... |